Search
Cytochlor
go.drugbank.com/drugs/DB12383InvestigationalCytochlor has been used in trials studying the treatment of Head and Neck Cancer and Brain and Central Nervous System Tumors.
Anagliptin
go.drugbank.com/drugs/DB12417InvestigationalAnagliptin is under investigation for the treatment of LDL Cholesterol, Coronary Disease, Diabetes Mellitus, Glycosylated Hemoglobin, and Dipeptidyl-Peptidase 4 Inhibitors.
HSD-016
go.drugbank.com/drugs/DB12419InvestigationalHsd 016 is under investigation in clinical trial NCT00838461 (Study Evaluating the Safety, Pharmacokinetics (PK), and Pharmacodynamices (PD) of HSD-016).
RCT1100
go.drugbank.com/drugs/DB18830InvestigationalRCT1100 is an investigational mRNA-based therapeutic that aims to treat primary ciliary dyskinesia caused by pathogenic mutations in DNAI1.[L50788]
Temelimab
go.drugbank.com/drugs/DB15634InvestigationalTemelimab is under investigation in clinical trial NCT02782858 (Clinical Trial Assessing the HERV-W Env Antagonist Gnbac1 for Efficacy in MS).
Loteprednol
go.drugbank.com/drugs/DB00873ApprovedInvestigationalWithdrawnLoteprednol is a corticosteroid. A more commonly used formulation of loteprednol is its ester, loteprednol etabonate.
Categories: Corticosteroid Hormone Receptor AgonistsLevonordefrin
go.drugbank.com/drugs/DB06707ApprovedInvestigationalLevonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry.
CM4620
go.drugbank.com/drugs/DB16466InvestigationalCM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066
Giloralimab
go.drugbank.com/drugs/DB18862InvestigationalWith IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis). … Giloralimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination
Palifermin
go.drugbank.com/drugs/DB00039ApprovedInvestigationalIt is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.[L17933]